TMOHealthcare · Diagnostics & ResearchThe 27 Wall Street analysts covering Thermo Fisher Scientific, Inc. hold a median 12-month price target of $660 — +1.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Thermo Fisher Scientific, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (94): The share price has been relatively steady.
Accruals (35): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TMO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1.2% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | UBS | Assumes | Buy | $540 → $730 |
| 3 Sept 2026 | CLSA | Initiates | Outperform | $748 |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | $620 → $650 |
| 27 July 2026 | Piper Sandler | Maintains | Neutral | — |
| 27 July 2026 | Piper Sandler | Maintains | Neutral | $510 → $600 |
| 24 July 2026 | Barclays | Maintains | Overweight | $625 → $650 |
| 24 July 2026 | Barclays | Maintains | Overweight | — |
| 24 July 2026 | RBC Capital | Maintains | Sector Perform | $490 → $580 |
| 24 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $575 → $570 |
| 26 June 2026 | Bernstein | Reinstates | Market Perform | $520 |
| 11 June 2026 | Piper Sandler | Initiates | Neutral | — |
| 3 June 2026 | HSBC | Downgrade | Hold | — |
| 2 June 2026 | Wolfe Research | Assumes | Outperform | $535 |
| 8 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 24 Apr 2026 | Baird | Maintains | Outperform | — |
| 24 Apr 2026 | Stifel | Maintains | Buy | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TMO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Thermo Fisher Scientific, Inc. returned +22.0% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Cheaper than 24% of US stocks
Cheaper than 22% of US stocks
Cheaper than 12% of US stocks
Higher than 53% of US stocks
Higher than 44% of US stocks
Higher than 50% of US stocks
Higher than 77% of US stocks
Higher than 78% of US stocks
Higher than 72% of US stocks
Higher than 77% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Thermo Fisher Scientific, Inc. has a market value of $244.8B and an enterprise value of $281.4B.
Revenue in the twelve months to 30 June 2026: $46.3B. The latest quarter grew 10.5% year on year.
Net income over the same four quarters: $7.0B, a 15.1% net margin.
Diluted earnings per share, trailing twelve months: $18.59.
Free cash flow in the twelve months to 30 June 2026: $7.3B.
Thermo Fisher Scientific, Inc. spent $5.0B on share buybacks and $662.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 34.3×; forward P/E: 23.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.29%, paying out 10% of earnings.
Thermo Fisher Scientific, Inc. employs 125,000 people — $371K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Thermo Fisher Scientific, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The item says Thermo Fisher's growth is gaining momentum, supported by innovation, acquisitions and strength across end markets, while noting ongoing macroeconomic and currency risks.
Why it matters — TMO watchers may weigh the growth drivers against the macroeconomic and currency risks highlighted in the report.
Zacks Investment Research published an Industry Outlook article in which Thermo Fisher Scientific, along with Globus Medical and Intuitive Surgical, was highlighted. The article focuses on the companies within the industry outlook context.
Why it matters — TMO watchers would care because the company is being featured in an industry-level analysis, which may signal how it is positioned within its sector.
Thermo Fisher Scientific announced it is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotech companies navigate increasingly complex commercialization paths. The company will showcase these new offerings, including OSD Express, at CPHI Milan 2026, held Oct. 6-8.
Why it matters — The expansion of Thermo Fisher's drug development and manufacturing offerings signals continued growth and competitive positioning in a key market for the company.
Zacks Investment Research highlights medical instruments companies including GMED, ISRG, and Thermo Fisher Scientific (TMO) as using generative AI to create growth opportunities amid industry challenges. The article notes that evolving regulations and industry risks are likely to shape how these companies adopt GenAI.
Why it matters — TMO watchers would care because the article points to GenAI adoption as a potential growth avenue for the company, while also flagging regulatory and industry risks that could influence how such technology is implemented.
Thermo Fisher Scientific announced that its strategic collaboration with PRECISE and NTU Singapore yielded the discovery of more than 2,500 previously unreported genetic-protein associations. The findings were enabled by combining Thermo Fisher's complementary proteomics technologies with PRECISE-SG100K's large-scale health and genomic data.
Why it matters — The result highlights the practical application and scientific impact of Thermo Fisher's proteomics technologies in large-scale research collaborations, underscoring their value in advancing biological discovery.
The 27 Wall Street analysts covering Thermo Fisher Scientific, Inc. have a median 12-month price target of $660, with estimates ranging from $560 to $780. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Thermo Fisher Scientific, Inc., 23 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Thermo Fisher Scientific, Inc. 82 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Thermo Fisher Scientific, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (94 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +1.2% from the last close, and Ticker Nerd's factor model ranks Thermo Fisher Scientific, Inc. 82 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Thermo Fisher Scientific, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $560 to $780 over the next 12 months.
Thermo Fisher Scientific, Inc. returned +22.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Thermo Fisher Scientific Inc. is a global life sciences company that provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services.
The most recent item we track (Zacks Investment Research, 7 Oct 2026): "Is This the Right Time to Add TMO Stock to Your Portfolio?". The item says Thermo Fisher's growth is gaining momentum, supported by innovation, acquisitions and strength across end markets, while noting ongoing macroeconomic and currency risks.
Thermo Fisher Scientific Inc. is a global life sciences company that provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services. Its portfolio supports scientific research, clinical testing, drug discovery, and pharmaceutical manufacturing through a broad range of instruments, reagents, consumables, software, and services. The company serves customers across pharmaceutical and biotechnology firms, hospitals, clinical diagnostic laboratories, universities, research institutions, and government agencies. Thermo Fisher Scientific Inc. operates through several business segments that address research, analysis, diagnostics, and laboratory workflow needs, making it an important supplier to healthcare, industrial, and scientific markets worldwide. Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. is recognized for its role in enabling laboratory productivity and supporting the development, testing, and production of modern therapies and diagnostics.
CEO Mr. Marc N. Casper · 125,000 employees · United States · https://www.thermofisher.com
